Pro-Dex (NASDAQ:PDEX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a research report released on Monday morning. The brokerage issued a buy rating on the medical instruments supplier’s stock.

Pro-Dex Trading Down 0.1 %

PDEX stock opened at $16.99 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.69 and a quick ratio of 1.39. The company has a fifty day moving average price of $16.49 and a two-hundred day moving average price of $17.46. Pro-Dex has a one year low of $12.40 and a one year high of $21.43. The stock has a market cap of $60.21 million, a price-to-earnings ratio of 16.50 and a beta of 0.99.

Pro-Dex (NASDAQ:PDEX – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The medical instruments supplier reported $0.24 EPS for the quarter. The firm had revenue of $11.28 million during the quarter. Pro-Dex had a net margin of 8.64% and a return on equity of 16.12%.

Institutional Investors Weigh In On Pro-Dex

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its position in shares of Pro-Dex by 345.6% in the third quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 2,084 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Pro-Dex in the second quarter valued at about $168,000. State Street Corp grew its stake in Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock worth $197,000 after buying an additional 650 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pro-Dex by 59.2% during the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 7,762 shares in the last quarter. Finally, LSV Asset Management increased its stake in Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after acquiring an additional 4,346 shares during the last quarter. Institutional investors own 13.49% of the company’s stock.

About Pro-Dex

(Get Rating)

Pro-Dex, Inc engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches.